Stockreport

TuHURA Biosciences: Potential In Immunotherapy Resistance, But How Will It Be Funded? [Seeking Alpha]

TuHURA Biosciences, Inc.  (HURA) 
PDF HURA's phase 3 trial for IFx-Hu2.0 in metastatic Merkel cell carcinoma is underway, with key data readouts not expected until 2026-2027. The company has less than one [Read more]